Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

SPDYE2L Inhibitors

SPDYE2L inhibitors pertain to a class of chemical compounds that are specifically designed to interact with the SPDYE2L protein, which plays a role in the complex network of protein-protein interactions within cells. SPDYE2L, an abbreviation from the protein's longer systematic name, is implicated in various cellular processes due to its involvement with other proteins and enzymes. Inhibitors targeting SPDYE2L are typically small molecules, though they can also encompass larger biomolecules. These inhibitors are characterized by their ability to bind to the SPDYE2L protein, and in doing so, they alter the protein's function. The binding affinity and specificity of these inhibitors are crucial for their effectiveness, and these properties are influenced by the molecular structure of the inhibitors, which often features a unique arrangement of atoms and functional groups engineered to interact with specific regions of the SPDYE2L protein.

The development of SPDYE2L inhibitors is a precise process that involves understanding the structural biology of the target protein. Researchers utilize a variety of techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, to determine the three-dimensional structure of SPDYE2L. This information is vital since the inhibitors must fit into the protein's active site or another relevant binding domain with high specificity. The design process often employs computational methods such as molecular docking and dynamics simulations to predict how potential inhibitors might interact with SPDYE2L. The chemical synthesis of these inhibitors is then undertaken, followed by a series of tests to assess their selectivity and ability to interact with the SPDYE2L protein. These compounds often exhibit high specificity, meaning they are designed to bind to SPDYE2L without significantly affecting other proteins, which is a key feature of their molecular profile. The study of SPDYE2L inhibitors is fundamentally rooted in biochemistry and molecular biology, focusing on the intricate dance of molecular interactions that underpin cellular function.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

A CDK4/6 inhibitor that impedes the cell cycle progression at G1, which may indirectly affect SPDYE2L by altering the cellular environment that modulates its expression or function due to cell cycle changes.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

A MEK inhibitor that blocks the MAPK/ERK pathway, potentially altering the phosphorylation state of proteins that interact with or regulate SPDYE2L, thereby affecting its activity.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A PI3K inhibitor that disrupts the PI3K/AKT pathway, which could indirectly impact the phosphorylation and activity of SPDYE2L if it is involved in signal transduction related to cell survival and proliferation.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Another PI3K inhibitor, similar to Wortmannin, that could affect SPDYE2L by interfering with downstream signaling events that may regulate its function.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor that can suppress cell growth and proliferation, potentially influencing SPDYE2L activity by changing the cellular growth conditions that may affect its regulation.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

A proteasome inhibitor that could lead to an accumulation of misfolded proteins, indirectly affecting SPDYE2L by altering proteostatic mechanisms that may involve SPDYE2L.

MLN8237

1028486-01-2sc-394162
5 mg
$220.00
(0)

An Aurora kinase A inhibitor that interferes with mitosis, potentially impacting SPDYE2L by affecting the cell cycle phases where SPDYE2L might play a role.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

A MEK inhibitor that, by blocking the MAPK/ERK pathway, could indirectly modulate the functional activity of SPDYE2L if it is involved in this signaling cascade.

AZD8055

1009298-09-2sc-364424
sc-364424A
10 mg
50 mg
$163.00
$352.00
12
(2)

An mTOR inhibitor that could affect SPDYE2L by changing the cellular growth and survival signals, potentially altering the conditions that regulate SPDYE2L function.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

A Src kinase inhibitor which may alter signaling pathways that involve SPDYE2L, especially if SPDYE2L is implicated in pathways modulating cell adhesion and migration.